Skip to content
April 25, 2024

Equity.Guru

Investment information for the new generation

Search

Mushrooms

In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the…
Several years back, Hugh Rogers was in my office talking about his cannabis company. Way back then, the plan was to grow in Germany and be first on the…
There’s no better due diligence in the psychoactive drug space than Health Canada. Loads of pharma companies have investor decks that promise they’ll one day be in the psychedelics…
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged…
I was feeling every ounce of my chest cold, the thing everyone apparently has, the one that’s going around, the one that’s not covid but who could tell. I…
The boss has told me to start running the rule over weed and psychedelics companies with a view to picking out anything that’s quietly profitable, or could be soon,…
Lophos Holdings (MESC.C) is a Canadian public company – the only public company – specifically focused on the quickly liberalizing psychedelics sub-sector of Peyote and Mescaline. You may be…
Revive Therapeutics (RVV.C), a company that specializes in creating treatments and tests for diseases that don’t have many existing options available, has made a deal with a health research…
A few weeks back, in what has become a seminal Equity.Guru piece about the quickly legalizing safe supply drug space, I tore into PharmaDrug (PHRX.C), which was lurching into…
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the…